Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Under the PMBJP, all the districts of the country are covered and ensure easy reach of affordable medicine to the people in every nook and corner of the country
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
With the acquisition of these further shares, TWPL has now become company's subsidiary.
The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The study was conducted in patients with mild to moderate COVID-19
The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
Subscribe To Our Newsletter & Stay Updated
